- Home
- EH vs ETNB Comparison
EH vs ETNB Comparison
Compare EH & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EH
- ETNB
- Stock Information
- Founded
- EH 2014
- ETNB 2018
- Country
- EH China
- ETNB United States
- Employees
- EH N/A
- ETNB N/A
- Industry
- EH Military/Government/Technical
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- EH Industrials
- ETNB Health Care
- Exchange
- EH Nasdaq
- ETNB Nasdaq
- Market Cap
- EH 1.2B
- ETNB 1.0B
- IPO Year
- EH 2019
- ETNB 2019
- Fundamental
- Price
- EH $18.27
- ETNB $7.77
- Analyst Decision
- EH Strong Buy
- ETNB Strong Buy
- Analyst Count
- EH 3
- ETNB 9
- Target Price
- EH $25.97
- ETNB $27.25
- AVG Volume (30 Days)
- EH 1.2M
- ETNB 1.5M
- Earning Date
- EH 05-19-2025
- ETNB 05-01-2025
- Dividend Yield
- EH N/A
- ETNB N/A
- EPS Growth
- EH N/A
- ETNB N/A
- EPS
- EH N/A
- ETNB N/A
- Revenue
- EH $62,494,280.00
- ETNB N/A
- Revenue This Year
- EH $113.39
- ETNB N/A
- Revenue Next Year
- EH $57.28
- ETNB N/A
- P/E Ratio
- EH N/A
- ETNB N/A
- Revenue Growth
- EH 288.46
- ETNB N/A
- 52 Week Low
- EH $10.40
- ETNB $4.16
- 52 Week High
- EH $29.76
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- EH 58.44
- ETNB 55.22
- Support Level
- EH $18.44
- ETNB $7.40
- Resistance Level
- EH $19.40
- ETNB $8.92
- Average True Range (ATR)
- EH 0.74
- ETNB 0.54
- MACD
- EH 0.51
- ETNB 0.14
- Stochastic Oscillator
- EH 92.84
- ETNB 59.74
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).